Search Results

You are looking at 1 - 10 of 61 items for :

  • "oophorectomy" x
Clear All
Full access

Susan M. Domchek, Jill E. Stopfer and Timothy R. Rebbeck

. References 1. Rebbeck TR Lynch HT Neuhausen SL . Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations . N Engl J Med 2002 ; 346 : 1616 – 1622 . 2. Kauff ND Satagopan JM Robson ME . Risk-reducing salpingo-oophorectomy in

Full access

Mod C. Chandhanayingyong, Nicholas M. Bernthal, Piti Ungarreevittaya, Scott D. Nelson, Sant P. Chawla and Arun S. Singh

subsequently confirmed with the R130Q mutation in her PTEN gene. In 2008, she had a complete hysterectomy with salpingo-oophorectomy for uterine fibroids, and in 2009 she had a complete thyroidectomy for multicystic adenomatous nodules with focal papillary

Full access

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Shrujal Baxi, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Elizabeth Kvale, Robin M. Lally, Terry S. Langbaum, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Deborah A. Freedman-Cass and Nicole R. McMillian

with a history of oophorectomy or chemotherapy and male survivors who received or are receiving androgen ablative therapies (ie, androgen deprivation therapy [ADT]). These symptoms can include hot flashes/night sweats, vaginal dryness, urinary

Full access

Srinivas K. Tantravahi, and Theresa L. Werner

tobacco, alcohol, or illicit drugs. In June 2011 she underwent laparoscopic total hysterectomy, bilateral salpingo-oophorectomy, and pelvic and para-aortic lymphadenectomy. Pathology revealed FIGO grade 1–2 endometrioid adenocarcinoma measuring 4.2 × 3

Full access

Kostandinos Sideras and Charles L. Loprinzi

additional reason for the increased problem with hot flashes in this population is the use of oophorectomy as a risk reduction strategy for some premenopausal women at increased risk, which induces immediate menopause and results in hot flashes in most

Full access

Jordan E. Rullo and Sandhya Pruthi

The greatest predictor of sexual dissatisfaction after risk-reducing salpingo oophorectomy (RRSO) is sexual dysfunction. 1 However, 60% to 80% of patients with BRCA report that they did not receive any information about sexual health

Full access

0040156 10.6004/jnccn.2006.0016 Bilateral Risk-Reducing Oophorectomy in BRCA1 and BRCA2 Mutation Carriers Domchek Susan M. MD Stopfer Jill E. MS, CGC Rebbeck Timothy R. PhD 02 2006 4 4 2 2 177 177 182 182 0040177 10.6004/jnccn

Full access

Wylie Burke and Nancy Press

oophorectomy in carriers of BRCA1 or BRCA2 mutations . N Engl J Med 2002 ; 346 : 1616 – 1622 . 7. Kauff ND Satagopan JM Robson ME . Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation . N Engl J Med 2002 ; 346

Full access

Janice S. Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L. Hammond and Mark S. Carey

tamoxifen); or (3) OA accomplished by outpatient laparoscopic bilateral salpingo-oophorectomy (BSO), followed by 5 years of an AI. We did not model the use of gonadotropin-releasing hormone (GnRH) agonist as a method of OA/AI, because there is no evidence

Full access

Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Michael Berry, Saundra S. Buys, Beth Crawford, Meagan Farmer, Susan Friedman, Judy E. Garber, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Huma Rana, Gwen Reiser, Mark E. Robson, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, Rashmi Kumar and Susan Darlow

-reducing salpingo-oophorectomy (RRSO) should be recommended or considered (ADDIT-2, page 159). Breast MRI is recommended when the gene mutation is associated with at least a 20% lifetime risk of breast cancer. This threshold was identified in breast cancer risk